ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,702.55
-0.19%
Dow Jones
42,063.36
0.09%
US Dollar vs MXN
19.4149
0.53%
Brent Oil
74.135
-0.25%
Bitcoin
63,246.17
0.47%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Revance Therapeutics Inc (RVNC)

  7. Revance Therapeutics Inc (RVNC) Noticias

RVNC

Revance Therapeutics (RVNC)

Revance Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:RVNC
FechaHoraFuenteTítuloSímboloCompañía
16/09/202416:01Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RVNCRevance Therapeutics Inc
09/09/202415:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
05/09/202416:27Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:RVNCRevance Therapeutics Inc
05/09/202415:45Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:RVNCRevance Therapeutics Inc
12/08/202414:18PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc.NASDAQ:RVNCRevance Therapeutics Inc
12/08/202407:00PR Newswire (US)Crown Laboratories and Revance Announce Entry Into Merger AgreementNASDAQ:RVNCRevance Therapeutics Inc
08/08/202415:34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RVNCRevance Therapeutics Inc
08/08/202415:05Business WireRevance Reports Second Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
01/08/202415:05Business WireRevance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024NASDAQ:RVNCRevance Therapeutics Inc
14/06/202415:05Business WireRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RVNCRevance Therapeutics Inc
28/05/202415:05Business WireRevance to Participate in Upcoming Investor ConferencesNASDAQ:RVNCRevance Therapeutics Inc
09/05/202415:06Business WireRevance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
09/05/202415:05Business WireRevance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical DystoniaNASDAQ:RVNCRevance Therapeutics Inc
02/05/202415:05Business WireRevance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:RVNCRevance Therapeutics Inc
12/04/202407:00Business WireRevance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingNASDAQ:RVNCRevance Therapeutics Inc
08/03/202415:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
05/03/202416:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RVNCRevance Therapeutics Inc
04/03/202408:25Business WireRevance Announces Pricing of $100.0 Million Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
04/03/202405:37Business WireRevance Announces Proposed Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
29/02/202415:36Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
28/02/202415:05Business WireRevance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
21/02/202407:01Business WireRevance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024NASDAQ:RVNCRevance Therapeutics Inc
14/02/202414:45Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
02/02/202407:00Business WireRevance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®NASDAQ:RVNCRevance Therapeutics Inc
01/02/202407:00Business WireRevance to Participate in the Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:RVNCRevance Therapeutics Inc
11/01/202405:18IH Market NewsWall Street Highlights: Mastercard’s Financial Rise, Citigroup’s $3.8 Billion Charges, and MoreNASDAQ:RVNCRevance Therapeutics Inc
08/01/202407:00Business WireRevance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial OutlookNASDAQ:RVNCRevance Therapeutics Inc
12/12/202304:50IH Market NewsHasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and MoreNASDAQ:RVNCRevance Therapeutics Inc
14/11/202315:22Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RVNCRevance Therapeutics Inc
08/11/202315:06Business WireRevance Reports Third Quarter 2023 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RVNC

Su Consulta Reciente

ASX
STOJOF
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados